Biosimilars Market to Reach USD 73.24 Billion by 2036: What Is Driving Growth

Healthcare systems around the world are under pressure to deliver advanced therapies at lower cost. Biologic medicines treat cancer, autoimmune disorders, and eye diseases, but their high prices strain budgets. This is where the Biosimilars Market is making a real difference. By offering highly similar alternatives to originator biologics, biosimilars are expanding patient access and bringing new competition to some of the world's most expensive drugs.

Market Overview and Growth Outlook

According to Polaris Market Research, the biosimilars market was valued at USD 35.22 billion in 2025. It is estimated at USD 37.54 billion in 2026 and is projected to reach USD 73.24 billion by 2036, growing at a CAGR of 6.9% from 2026 to 2036.

A biosimilar is a biological medicine shown to be highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Unlike conventional generics, which are chemical copies of small-molecule drugs, biosimilars are made in living systems and need extensive analytical and comparative evidence. In the US they are approved through the abbreviated 351(k) pathway.

Key Factors Driving Market Growth

The first driver is the patent expiry of high-revenue biologics. As exclusivity ends on major products, manufacturers are advancing biosimilar programs for pembrolizumab, nivolumab, omalizumab, ocrelizumab, and high-dose aflibercept. Keytruda's primary compound patent is due to expire in December 2028, which is already pushing companies like Samsung Bioepis, Formycon, and Amgen to move their candidates forward.

The second driver is rising regulatory approvals. The FDA approved 18 biosimilars in 2025 alone, showing steady momentum in the approval pipeline.

The third driver is interchangeability. Interchangeable biosimilars can be substituted at the pharmacy level where state law allows, without a new prescriber authorization. As of January 2026, 25 of the 90 FDA-approved biosimilars carried this designation. Interchangeable products are projected to grow at the fastest rate in their segment, at an 8.92% CAGR through 2036.

Segment Insights

By drug class, monoclonal antibodies dominated with a 46.18% share in 2025, anchored by adalimumab, which alone has 10 FDA-approved biosimilars. TNF-alpha inhibitors held 14.72%, insulins 11.36%, and G-CSF agents 9.84%. VEGF inhibitors are expected to grow fastest, at an 8.12% CAGR, supported by multiple aflibercept programs in ophthalmology.

By therapeutic area, oncology led with a 38.64% share in 2025 and is projected to grow at 8.36% through 2036. Autoimmune and inflammatory disorders followed with 35.27%, while ophthalmology and diabetes also contribute meaningfully.

By distribution channel, hospital pharmacies held the largest share at 58.37%, supported by infused oncology products. Retail and specialty pharmacies accounted for 34.21% and are growing steadily. One example is Boehringer Ingelheim's unbranded adalimumab biosimilar, offered through GoodRx at $550 per two-pack, roughly 92% below Humira's list price. Online and cash-pay platforms, though smaller, are projected to grow at a 9.26% CAGR.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/biosimilars-market

Regional Trends

North America led the market with a 34.68% share in 2025, supported by active FDA approvals, mature payer systems, and strong specialty pharmacy networks.

Europe held 31.54%, benefiting from two decades of biosimilar experience and tender-based procurement. Teva's aflibercept biosimilar AHZANTIVE reached patients in France, Germany, Spain, and the Netherlands in 2026.

Asia Pacific is the fastest-growing region, with a projected CAGR of 8.47%. Strong development activity in China, South Korea, and India is backed by deals like the one between Henlius and Sandoz, worth up to USD 322 million. Latin America held about 4.11% of the market in 2025, while the Middle East and Africa is expected to grow at 7.56% as local licensing and manufacturing partnerships expand.

Opportunities and Challenges

Oncology checkpoint inhibitors offer the biggest opportunity. Pembrolizumab and nivolumab are used by large patient populations, and indication extrapolation can widen the addressable market once regulatory requirements are met. Licensing and commercialization partnerships are also helping manufacturers enter new geographies without building everything from scratch.

Challenges remain. Biosimilar manufacturing needs specialized facilities, cell-line development, and process validation, which raises entry costs. Originator rebate strategies can also narrow the real price gap, since a lower list price does not always mean a lower net cost. Patent litigation adds further uncertainty, as shown by the recent legal action over Amgen's nivolumab biosimilar.

Competitive Landscape

The market is consolidating around players with strong regulatory, clinical, and manufacturing capabilities. Key companies include Sandoz, Amgen, Pfizer, Celltrion, Samsung Bioepis, Biocon Biologics, Teva, Fresenius Kabi, Boehringer Ingelheim, and Alvotech. Success increasingly depends on interchangeability status, formulary access, and payer engagement, not just approval volume.

Conclusion

The Biosimilars Market is set to nearly double, from USD 35.22 billion in 2025 to USD 73.24 billion by 2036. Patent expiries, expanding interchangeable designations, strong oncology pipelines, and growing partnerships across Asia Pacific and emerging regions will shape this growth. For manufacturers, payers, and healthcare providers, biosimilars are becoming a core strategy for delivering effective biologic treatment at a more sustainable cost.

More Trending Latest Reports By Polaris Market Research:

Healthcare It Market

US Spatial Genomics and Transcriptomics Market

Grafted Polyolefins Market

Aerospace Composites Market

US Spatial Genomics and Transcriptomics Market

Dropshipping Market

Age-Related Macular Degeneration (Amd) Market

Glass Bonding Adhesives Market To Witness Owing To Enhanced Usage To Bond A Variety Of Substrates Wi

In-Building Wireless Market